NPPA Fixes Retail Price of 65 New Drugs, Ceiling Price of 20 Formulations, Details
New Delhi: Through recent notifications, the National Pharmaceutical Pricing Authority (NPPA), under the Ministry of Chemicals and Fertilizers, has fixed the maximum retail price of 65 new drugs, along with determining the ceiling price for 13 scheduled formulations. Additionally, the Authority has also revised the ceiling price for 7 formulations including WPI impact @0.00551% for the year 2024.
In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. 1548(E) dated 26th March, 2024 in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
| S. No | Medicine | Dosage Form and Strength | Unit | Ceiling Price (₹) |
| 1 | Anti-rabies immunoglobulin | Injection 150 IU/ml | 1 ML | 3,107.59 |
| 2 | Anti-rabies immunoglobulin | Injection 300 IU/ml | 1 ML | 109.56 |
| 3 | Measles vaccine | As licensed | Each vial of 0.5ml | 50.20 |
| 4 | Anti-tetanus immunoglobulin | As licensed (250 IU) | 1 Vial | 1,244.79 |
| 5 | Anti-tetanus immunoglobulin | As licensed (500 IU) | 1 Vial | 1,875.75 |
| 6 | Anti-tetanus immunoglobulin | As licensed (1000 IU) | 1 Vial | 2,684.19 |
| 7 | BCG vaccine | As licensed | Each dose (0.10 ML) | 8.01 |
| 8 | Measles Rubella vaccine | As licensed | Each vial of 0.5ml | 71.19 |
| 9 | Amphotericin B Liposomal | Injection 50mg/vial | 1 Vial | 6,648.23 |
| 10 | Amphotericin B Lipid | Injection 50mg/vial | 1 Vial | 1,887.75 |
| 11 | Water for injection | Injection | Each pack (10 ml) | 2.42 |
| 12 | Budesonide + Formoterol (MDI) | 400 mcg + 6 mcg | Per Metered Dose | 3.37 |
| 13 | Budesonide + Formoterol (MDI) | 200 mcg + 6 mcg | Per Metered Dose | 2.96 |
Revised Ceiling Prices Considering WPI Adjustment
A second notification revises ceiling price further, factoring in the Wholesale Price Index (WPI) impact of 0.00551%.
In implementation of directions of review order issued by the Department of Pharmaceuticals (DOP) under para 31 of Drugs (Prices Control) Order, 2013 vide order specified in column (7) of the table below and in exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. and date specified in the Column (8) of the table, the National Pharmaceutical Pricing Authority, hereby fixes/revises the price including WPI impact @0.00551% for the year 2024 as specified in column (6) of the table herein below as ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
| S. No | Medicine | Dosage Form & Strength | Unit | Old Ceiling Price (₹) | Revised Price (₹) | Review Order and Date | Previous SO and Date |
| 1 | Thiamine | Injection 100 mg/ml | 1 ml | 22.59 | 26.70 | 31015/45/2023Pricing (04.10.2024) | 1547(E) (26.03.2024, Sl. No. 652) |
| 2 | Clarithromycin | Oral Liquid 125mg/5ml | 1 ml | 4.61 | 4.65 | 31015/38/2023Pricing (04.10.2024) | 1547(E) (26.03.2024, Sl. No. 151) |
| 3 | Lignocaine | Injection 2% | 1 ml | 1.04 | 1.14 | 31015/46/2023Pricing (04.10.2024) | 1547(E) (26.03.2024, Sl. No. 405) |
| 4 | Lignocaine | Topical forms 2-5% | 1 gm/ml | 1.13 | 1.08 | 31015/46/2023Pricing (04.10.2024) | 1547(E) (26.03.2024, Sl. No. 404) |
| 5 | Clarithromycin | Tablet 250 mg | 1 tablet | 23.89 | 24.06 | 31015/86/2023Pricing (04.10.2024) | 1547(E) (26.03.2024, Sl. No. 149) |
| 6 | Ascorbic Acid | Tablet 500 mg | 1 tablet | 1.48 | 1.54 | 31015/68/2023Pricing (04.10.2024) | 1547(E) (26.03.2024, Sl. No. 55) |
| 7 | Atorvastatin | Tablet 10 mg | 1 tablet | 4.94 | 4.97 | 31015/86/2023Pricing (04.10.2024) | 1547(E) (26.03.2024, Sl. No. 59) |
NPPA also notified the MRP for various antiviral, cardiology, antibiotic, anti-diabetic, and vitamin formulations. In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the Table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
TABLE
| S. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (in Rs.) |
| (1) | (2) | (3) | (4) | (5) | (6) |
| 1 | Acebrophylline and N-Acetylcysteine Tablets | Each film coated tablet contains: Acebrophylline 100 mg N-Acetylcysteine Ph. Eur. 600 mg | 1 Tablet | M/s Win Medicare Pvt. Ltd./ M/s Modi- Mundipharma Pvt. Ltd. | 14.31 |
| 2 | Acyclovir SustainedRelease Tablets | Each uncoated sustained-release tablet contains: Acyclovir IP 1200mg | 1 Tablet | M/s Rivpra Formulation Pvt. Ltd. / M/s Mankind Pharma Ltd. | 56.21 |
| 3 | Atorvastatin & Ezetimibe Tablets | Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 40 mg Ezetimibe IP 10 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Sun Pharma Laboratories Limited | 34.65 |
| 4 | Atorvastatin & Ezetimibe Tablets | Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 40 mg Ezetimibe IP 10 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Sun Pharmaceutical Industries Limited | 34.65 |
| 5 | Atorvastatin & Ezetimibe Tablets | Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 20 mg Ezetimibe IP 10 mg | 1 Tablet | M/s Sun Pharma Laboratories Limited/ M/s Sun Pharmaceutical Industries Limited | 27.38 |
| 6 | Atorvastatin & Ezetimibe Tablets | Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 20 mg Ezetimibe IP 10 mg | 1 Tablet | M/s Sun Pharma Laboratories Limited | 27.38 |
| 7 | Dispersible Amoxycillin & Potassium Clavulanate Tablets BP | Each uncoated dispersible tablet contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 400 mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 57 mg | 1 Tablet | M/s Malik Lifesciences Pvt. Ltd./ M/s Micro Labs Ltd. | 24.66 |
| 8 | Bisoprolol Fumarate and Amlodipine tablets | Each film coated tablet contains: Bisoprolol Fumarate IP 5 mg Amlodipine besylate IP eq. to Amlodipine 5 mg | 1 Tablet | M/s Dr. Miltons Laboratories Pvt. Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd. | 8.40 |
| 9 | Bisoprolol Fumarate and Amlodipine tablets | Each film coated tablet contains: Bisoprolol Fumarate IP 2.5 mg Amlodipine besylate IP eq. to Amlodipine 5 mg | 1 Tablet | M/s Dr. Miltons Laboratories Pvt. Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd. | 6.32 |
| 10 | Cefuroxime Axetil and Potassium clavulanate Tablets | Each film coated tablet contains: Cefuroxime Axetil IP eq. to Cefuroxime 500 mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 125 mg | 1 Tablet | M/s Alps communication Pvt. Ltd./ M/s Aristo Laboratories Pvt. Ltd. | 58.08 |
| 11 | Cefuroxime Axetil & Potassium Clavulanate Tablets | Each film coated tablet contains: Cefuroxime Axetil IP eq. to Cefuroxime 500mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 125mg | 1 Tablet | M/s Innova Captab Limited /M/s Dr. Reddy's Laboratories Limited | 58.08 |
| 12 | Vitamin D3 Oral Drops | Each ml contains: Cholecalciferol (Vitamin D3) IP 800 IU | 1 ml | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Alkem Laboratories Ltd. | 5.75 |
| 13 | Cholecalciferol (Vitamin D3) oral solution | Each 5 ml contains: Cholecalciferol IP (in nano droplet form) 60000IU | 1 ml | M/s Ravenbhel Healthcare Pvt. Ltd./ M/s Aristo Laboratories Pvt. Ltd. | 18.93 |
| 14 | Cholecalciferol (Vitamin D3) oral solution | Each 5 ml contains: Cholecalciferol IP 60000IU | 1ml | M/s Ravenbhel Healthcare Pvt. Ltd./ M/s Macleods Pharmaceuticals Ltd. | 20.23 |
| 15 | Cilnidipine & Metoprolol Succinate (ER) Tablets | Each film coated bilayered tablet contains: Cilnidipine 10mg Metoprolol Succinate USP 23.75mg eq. to Metoprolol Tartrate 25mg (in extended-release form) | 1 Tablet | M/s Ravenbhel Biotech / M/s Mankind Pharma Ltd. | 9.91 |
| 16 | Cilnidipine & Metoprolol Succinate (ER) Tablets | Each film coated bilayered tablet contains: Cilnidipine 10mg Metoprolol Succinate USP 47.5mg eq. to Metoprolol Tartrate 50mg (in extended release form) | 1 Tablet | M/s Ravenbhel Biotech/ M/s Mankind Pharma Ltd. | 11.02 |
| 17 | Dextromethorphan Hydrobromide, Bilastine & Phenylephrine Hydrochloride Syrup | Each 5ml contains: Dextromethorphan Hydrobromide IP 10mg Bilastine IP 3.3mg Phenylephrine Hydrochloride IP 5mg | 1ml | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Akumentis Healthcare Ltd. | 1.17 |
| 18 | Diclofenac Injection IP | Each ml contains: Diclofenac sodium IP 75 mg | 1ml | M/s Nitin Lifesciences Ltd /M/s Aristo Laboratories Pvt. Ltd. | 31.38 |
| 19 | Esomeprazole and Domperidone Sustained Release capsules | Each hard gelatin capsule contains: Esomeprazole Magnesium IP eq. to Esomeprazole 40 mg (as enteric coated pellets) Domperidone Maleate IP eq. to Domperidone 30 mg (sustained release) | 1 Capsule | M/s Windlas Biotech Ltd./ M/s Intas Pharmaceuticals Ltd. | 12.39 |
| 20 | Esomeprazole & Domperidone Capsules | Each hard gelatin capsule contains: Esomeprazole Magnesium Trihydrate IP eq. to Esomeprazole 40 mg (as enteric coated pellets) Domperidone IP 30 mg (as sustained release pellets) | 1 Capsule | M/s Pure & Cure Healthcare Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd. | 12.50 |
| 21 | Etamsylate & Tranexamic Acid Tablets | Each film coated tablet contains: Etamsylate BP 250 mg Tranexamic Acid IP 250 mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd. | 19.59 |
| 22 | Glimepiride IP, Voglibose IP, Metformin Hydrochloride (SR) tablets | Each uncoated bilayered tablet contains: Glimepiride IP 0.5 mg, Voglibose IP 0.2 mg, Metformin Hydrochloride IP (as sustained release form) 500 mg | 1 Tablet | M/s Windlas Biotech Limited/ M/s Intas Pharmaceuticals Ltd. | 9.12 |
| 23 | Gliclazide MR & Metformin Hydrochloride ER tablets | Each uncoated bilayered tablet contains: Metformin Hydrochloride (in extended release form) IP 500 mg Gliclazide (in modified release form) IP 30 mg | 1 Tablet | M/s Unison Pharmaceuticals Pvt. Ltd | 7.46 |
| 24 | Gliclazide MR & Metformin Hydrochloride ER tablets | Each uncoated bilayered tablet contains: Metformin Hydrochloride (in extended release form) IP 500 mg Gliclazide (in modified release form) IP 60 mg | 1 Tablet | M/s Unison Pharmaceuticals Pvt. Ltd | 9.74 |
| 25 | Glimepiride, Voglibose IP, Metformin Hydrochloride IP (as sustained release form) tablets | Each uncoated bilayered tablet contains: Glimepiride IP 0.5mg Voglibose IP 0.2mg Metformin Hydrochloride IP 500mg (as sustained release form) | 1 Tablet | M/s Windlas Biotech Ltd./ M/s Lupin Limited | 9.12 |
| 26 | Glimepiride, Voglibose and Metformin Hydrochloride (ER) tablets | Each uncoated bi-layered tablet contains: Glimepiride IP 1mg, Voglibose IP 0.2mg and Metformin Hydrochloride IP 500mg (ExtendedRelease form) | 1 Tablet | M/s Mascot Health Series Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd. | 11.62 |
| 27 | Glimepiride, Voglibose and Metformin Hydrochloride (ER) tablets | Each uncoated bi-layered tablets contains: Glimepiride IP 2 mg, Voglibose IP 0.2mg and Metformin Hydrochloride IP 500mg (ExtendedRelease form) | 1 Tablet | M/s Mascot Health Series Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd. | 14.79 |
| 28 | Itraconazole Capsules BP | Each hard gelatin capsule contains: Itraconazole BP 50 mg | 1 Capsule | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Biological E. Limited | 11.51 |
| 29 | Multivitamin & Multimineral Drops | Each ml contains : Cholecalciferol (as Stabilized)IP 200 IU Pyridoxine HCl IP 0.5mg Niacinamide IP 5mg Cyanocobalamin IP 1mcg Sodium Selenite Pentahydrate BP eq. to elemental Selenium 10 mcg Zinc Sulphate Monohydrate IP eq. to elemental Zinc 2 mg Manganese sulphate Monohydrate BP eq. to elemental Manganese 3 mcg Sodium molybdate dihydrate BP eq. to elemental Molybdenum 1 mcg L-Lysine Hydrochloride IP 30 mg Potassium Iodide IP eq. to elemental Iodine 20 mcg Biotin IP 5 mcg Chromium Picolinate IP eq. to elemental Chromium 1 mcg Myo-Inositol IP 10 mg Beta Carotene Dispersion 2.5% 18 mg | 1 ml | M/s Ordain Health Care Global Pvt. Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd. | 3.10 |
| 30 | Pantoprazole & Cinitapride SR capsules | Each hard gelatin capsule contains: Pantoprazole Sodium IP eq. to Pantoprazole 40 mg (as enteric coated tablet) Cinitapride Hydrogen tartrate eq. to Cinitapride (as Sustained release tablet)3 mg | 1 Capsule | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Dr. Reddy's Laboratories Ltd. | 24.82 |
| 31 | Paracetamol & Mefenamic Acid Suspension | Each 5 ml contains: Paracetamol IP 250 mg Mefenamic Acid IP 100 mg | 1 ml | M/s Tirupati Medicare Ltd./ M/s Dr. Reddy's Laboratories Limited | 0.92 |
| 32 | Paracetamol and Mefenamic Acid Suspension | Each 5 ml contains: Paracetamol IP 125 mg Mefenamic Acid IP 50 mg | 1 ml | M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd. | 0.73 |
| 33 | Paracetamol IP & Mefenamic Acid Suspension | Each 5 ml contains: Paracetamol IP 125 mg Mefenamic Acid IP 50 mg | 1 ml | M/s Tirupati Medicare Limited / M/s Dr. Reddy's Laboratories Limited | 0.73 |
| 34 | Riboflavin, Folic Acid Niacinamide & Lactic Acid Bacillus Spores Tablets | Each uncoated tablet contains: Riboflavin IP 10mg Folic Acid IP 1.5mg Niacinamide IP 100mg Lactic Acid Bacillus Spores 60 million | 1 Tablet | M/s Marine Medicare Pvt. Ltd. / M/s Nicholas Healthcare Limited | 4.25 |
| 35 | Sodium Alginate, Sodium Bicarbonate, Calcium Carbonate Oral Suspension | Each 5 ml contains: Sodium Alginate IP 250 mg Sodium Bicarbonate IP 133.5 mg Calcium Carbonate IP 80 mg | 1 ml | M/s Windlas Biotech Ltd./ M/s Biological E. Ltd. | 0.83 |
| 36 | Tacrolimus Ointment | Composition: Tacrolimus I.P. eq. to Anhydrous Tacrolimus 0.1%w/w | 1 gm | M/s Rivpra Formulation Pvt. Ltd./ M/s RPG Life Sciences Ltd. | 35.64 |
| 37 | Telmisartan & Chlorthalidone Tablets | Each uncoated tablet contains: Telmisartan IP 40 mg Chlorthalidone IP 12.5 mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd. | 11.59 |
| 38 | Telmisartan & Cilnidipine Tablets | Each film coated tablet contains: Telmisartan IP 40 mg Cilnidipine IP 10 mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd. | 11.11 |
| 39 | Telmisartan & Cilnidipine Tablets | Each film coated bilayered tablet contains: Telmisartan IP 80 mg Cilnidipine IP 10 mg | 1 Tablet | M/s Macleods Pharmaceuticals Ltd. | 16.10 |
| 40 | Telmisartan & Indapamide tablets | Each uncoated bilayered tablet contains: Telmisartan IP 40mg Indapamide IP 1.5mg (as sustained release) | 1 Tablet | M/s Windlas Biotech Ltd. / M/s Eris Lifesciences Limited | 13.25 |
| 41 | Telmisartan, Cilnidipine and Chlorthalidone tablets | Each film coated tablet contains: Telmisartan IP 40 mg Cilnidipine IP 10 mg Chlorthalidone IP 12.50 mg |
1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Torrent Pharmaceuticals Ltd. | 15.15 |
| 42 | Telmisartan, Amlodipine and Hydrochlorothiazide Tablets | Each film coated tablet contains: Telmisartan IP 40 mg Amlodipine Besylate IP eq. to Amlodipine 5 mg Hydrochlorothiazide IP 12.5 mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd. | 11.00 |
| 43 | Tranexamic Acid and Mefenamic Acid tablets | Each film coated tablet contains: Tranexamic Acid IP 500 mg Mefenamic Acid IP 250 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Pharmed Limited | 31.50 |
| 44 | Dapagliflozin, Glimepiride, Metformin Hydrochloride (extended release) tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10 mg, Glimepiride IP 1 mg, Metformin Hydrochloride (extended release) IP 500 mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd. | 12.42 |
| 45 | Dapagliflozin, Glimepiride, Metformin Hydrochloride (extended release) tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10 mg, Glimepiride IP 2 mg, Metformin Hydrochloride IP 500 mg (extended release) | 1 Tablet | M/s Mascot Health Series Pvt. Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd. | 12.42 |
| 46 | Dapagliflozin, Glimepiride, Metformin Hydrochloride (extended release) tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10 mg, Glimepiride IP 1 mg, Metformin Hydrochloride (extended release) IP 500 mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd./ M/s Alembic Pharmaceuticals Ltd. | 12.42 |
| 47 | Dapagliflozin, Glimepiride, Metformin Hydrochloride (extended release) tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10 mg, Glimepiride IP 2 mg, Metformin Hydrochloride (extended release) IP 500 mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd./ M/s Alembic Pharmaceuticals Ltd. | 12.42 |
| 48 | Sitagliptin, Dapagliflozin and Metformin Hydrochloride (extended release) Tablets | Each film coated bilayered tablet contains: Sitagliptin phosphate monohydrate IP eq. to Sitagliptin 100mg Dapagliflozin propanediol USP eq. to Dapagliflozin 10mg Metformin hydrochloride IP (as extended release form) 1000mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd/ M/s FDC limited | 18.21 |
| 49 | Sitagliptin, Dapagliflozin and Metformin Hydrochloride (extended release) Tablets | Each film coated bilayered tablet contains: Sitagliptin phosphate monohydrate IP eq. to Sitagliptin 100mg Dapagliflozin propanediol USP eq. to dapagliflozin 10mg Metformin hydrochloride IP (as extended release form) 500mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd/ M/s FDC Limited | 17.26 |
| 50 | Sitagliptin, Pioglitazone and Metformin Hydrochloride (sustained release) Tablets | Each film coated bilayered tablet contains: Sitagliptin phosphate monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg Metformin hydrochloride IP (as sustained release form) 500mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Cadila Pharmaceuticals Ltd. | 14.15 |
| 51 | Sitagliptin, Pioglitazone and Metformin Hydrochloride (sustained release) Tablets | Each film coated bilayered tablet contains: Sitagliptin phosphate monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg Metformin hydrochloride IP (as sustained release form) 1000mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Cadila Pharmaceuticals Ltd. | 15.43 |
| 52 | Sitagliptin & Metformin Hydrochloride tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Blue Cross Laboratories Pvt. Ltd. | 9.00 |
| 53 | Sitagliptin & Metformin Hydrochloride tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Metformin Hydrochloride IP 1000 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Blue Cross Laboratories Pvt. Ltd. | 9.87 |
| 54 | Vildagliptin (SR) & Metformin Hydrochloride (SR) tablets | Each film coated bilayered tablet contains: Vildagliptin IP 100 mg (as sustained release form) Metformin Hydrochloride IP 500 mg (as sustained release form) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd. | 10.24 |
| 55 | Vildagliptin (SR) & Metformin Hydrochloride (SR) tablets | Each film coated bilayered tablet contains: Vildagliptin IP 100 mg (as sustained release form) Metformin Hydrochloride IP 1000 mg (as sustained release form) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd. | 11.55 |
| 56 | Linagliptin & Metformin Hydrochloride (ER) tablets | Each film coated bilayered tablet contains: Linagliptin 5 mg Metformin hydrochloride IP (as extended release form) 500 mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. /M/s Eris Lifesciences Limited | 10.68 |
| 57 | Ceftazidime and Avibactam Powder for concentrate Solution for Infusion | Each vial contains: Sterile Ceftazidime Pentahydrate IP eq. to Anhydrous Ceftazidime 2 gm Sterile Avibactam sodium eq. to Avibactam 0.5 gm | 1 vial | M/s GMH Organics/ M/s Aurobindo Pharma Limited | 1422.21 |
| 58 | Ceftriaxone, Disodium Edetate and Sulbactam Powder for Solution for Infusion | Each vial contains: Ceftriaxone Sodium IP eq. to Ceftriaxone 1000mg Sulbactam Sodium IP eq. to Sulbactam 500mg Disodium Edetate IP 37mg | 1 vial | M/s Alkem Health Science (A Unit of Alkem Laboratories Ltd.) / M/s Alkem Laboratories Ltd | 515.57 |
| 59 | Ceftriaxone, Disodium Edetate and Sulbactam Powder for Solution for Infusion | Each vial contains: Ceftriaxone Sodium IP eq. to Ceftriaxone 2000mg Sulbactam Sodium IP eq. to Sulbactam 1000mg Disodium Edetate IP 74mg | 1 vial | M/s Alkem Health Science (A Unit of Alkem Laboratories Ltd.) / M/s Alkem Laboratories Ltd | 1036.60 |
| 60 | Empagliflozin & Metformin Hydrochloride Tablets | Each film coated tablet contains: Empagliflozin 5 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Cipla Ltd. | 8.50 |
| 61 | Empagliflozin & Metformin Hydrochloride Tablets | Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Cipla Ltd. | 12.00 |
| 62 | Ferrous Bisglycinate, Folic Acid, Zinc Bis-glycinate & Vitamin B12 (Cyanocobalamin) Tablets | Each film coated tablet contains: Ferrous Bis-glycinate eq. to Elemental Iron 60mg Zinc Bis-glycinate eq. to Elemental Zinc 15mg Folic Acid IP 1mg Vitamin B12 IP 15mcg (Cyanocobalamin) | 1 Tablet | M/s Windlas Biotech Limited / M/s Biological E. Limited | 8.17 |
| 63 | Iron tonic with Vitamin B12 and Folic Acid | Each 5ml contains: Ferric Ammonium Citrate IP 80mg Folic Acid IP 0.166mg Vitamin B12 IP 1mcg | 1 ml | M/s Aagya Biotech Pvt. Ltd. / M/s J. B. Chemicals & Pharmaceuticals Ltd. | 0.45 |
| 64 | Atorvastatin and Ezetimibe tablets | Each film coated tablet contains: Atorvastatin Calcium IP equivalent to Atorvastatin 80 mg, Ezetimibe IP 10mg | 1 Tablet | M/s Windlas Biotech ltd./ M/s Intas pharmaceuticals Ltd. | 50.00 |
| 65 | Famotidine, Calcium Carbonate & Magnesium Hydroxide Chewable Tablets | Each chewable tablet contains: Famotidine IP 10mg Calcium Carbonate IP 800mg Magnesium Hydroxide IP 165mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Akumentis Healthcare Ltd. | 5.30 |
Additionally, the notifications mentioned that manufacturers of scheduled formulations selling their products above the specified ceiling price, including applicable Goods and Services Tax (GST), are required to revise their prices downward to comply with the ceiling price set by the National Pharmaceutical Pricing Authority (NPPA). If the manufacturers already sell these products at a price lower than the ceiling, they must maintain their current Maximum Retail Price (MRP) in line with paragraph 13(2) of the Drugs (Prices Control) Order (DPCO), 2013. Additionally, GST can only be added to the ceiling price if it has actually been paid or is payable to the government.
The determination of the ceiling price must adhere to the provisions outlined in paragraph 11 of the DPCO, 2013. Manufacturers are required to issue updated price lists (Form-V) from the date of the notification and submit these to the NPPA via the Integrated Pharmaceutical Database Management System (IPDMS), as well as to State Drug Controllers and dealers. Retailers and dealers are obligated to display the price list and any supplementary updates in a conspicuous location within their business premises to ensure easy access for consumers.
If a manufacturer introduces a new drug with dosage or strength specified in the schedule, they must apply for prior price approval from the NPPA, following the guidelines in Schedule II of the DPCO, 2013. Regular reporting is also mandatory, with quarterly returns detailing production, import, and sales of scheduled formulations to be submitted via Form-III. In cases of production discontinuation, manufacturers must notify the NPPA at least six months in advance through Form-IV.
Non-compliance with these regulations will result in penalties, including the repayment of overcharged amounts with interest. Such violations fall under the purview of the DPCO, 2013, and the Essential Commodities Act, 1955. Finally, this notification supersedes any prior price orders for the listed formulations, ensuring uniform implementation of the revised ceiling prices.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.